CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Cannabidiol +1 moredrug
Likely dose
Cannabidiol 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03102918
NCT03102918Phase 1Completed
CompareCT.gov

Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder

Mclean Hospital·interventional·Posted Apr 6, 2017·Updated Jan 25, 2019

In Brief

A Phase 1 clinical trial evaluating Cannabidiol and Placebo for Cannabis Use Disorder. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance, and cigarette use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 6, 2017
Enrollment StartFeb 20, 2016
Primary CompletionAug 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.2 years ago

Interventions

Cannabidioldrug

Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.

Placebodrug

Participants will receive placebo over a 6-week treatment period.